Thursday, April 16, 2026
Financial TimesPortada

China to drive a weight-loss drug price war

The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale

R
Redacción
Newsroom · Hace 19 h
2 min read
The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale